← Back to Search

Long-Term Follow-Up of Patients who Received ATL001 for Non-Small Cell Lung Cancer and Melanoma

Phase 2
Waitlist Available
Research Sponsored by Achilles Therapeutics UK Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have received ATL001 in previous Clinical Trial ATX-NS-001 or ATX-ME-001.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 4 months to 60 months; then every 6 months until death or until the end of the study, whichever came first, assessed up to 84 months.
Awards & highlights

Study Summary

This trial is looking at the long-term safety and effectiveness of a drug that has been previously administered to patients in other studies.

Eligible Conditions
  • Melanoma
  • Non-Small Cell Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have participated in a previous clinical trial that tested ATL001 called ATX-NS-001 or ATX-ME-001.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 4 months to 60 months; then every 6 months until death or until the end of the study, whichever came first, assessed up to 84 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 4 months to 60 months; then every 6 months until death or until the end of the study, whichever came first, assessed up to 84 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of adverse events to evaluate long-term Safety and Tolerability of ATL001
Assessment of autoimmune adverse events
Malignant Neoplasms
+1 more
Secondary outcome measures
Assessment for Overall Survival (OS)
Assessment for cancer-related medical resources
Disease Assessment for Duration of Response ( DoR)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001Experimental Treatment1 Intervention
Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001
Group II: Experimental: ATL001Experimental Treatment1 Intervention
Patients who have previously received ATL001 in a clinical trial will be evaluated in this trial for long-term safety and clinical activity.

Find a Location

Who is running the clinical trial?

Achilles Therapeutics UK LimitedLead Sponsor
3 Previous Clinical Trials
490 Total Patients Enrolled
1 Trials studying Melanoma
40 Patients Enrolled for Melanoma
Medical Monitor, MDStudy DirectorAchilles Therapeutics UK Limited
72 Previous Clinical Trials
18,075 Total Patients Enrolled
1 Trials studying Melanoma
40 Patients Enrolled for Melanoma

Media Library

Experimental: ATL001 Clinical Trial Eligibility Overview. Trial Name: NCT04785365 — Phase 2
Melanoma Research Study Groups: Experimental: ATL001, Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001
Melanoma Clinical Trial 2023: Experimental: ATL001 Highlights & Side Effects. Trial Name: NCT04785365 — Phase 2
Experimental: ATL001 2023 Treatment Timeline for Medical Study. Trial Name: NCT04785365 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still room for participants in this trial?

"Clinicaltrials.gov reveals that this medical study, which was originally posted on June 1st 2022 and last updated February 15th 2022 is no longer actively recruiting participants. Nevertheless, a plethora of other studies are currently searching for individuals to join their trial - 2060 in total."

Answered by AI

What are the chief objectives of this experiment?

"According to the study's sponsor, Achilles Therapeutics UK Limited, its main objective is assessment of autoimmune adverse events over a span lasting between 4 months and 84 months (or until death or the end of the trial). Secondary outcomes which will be monitored include duration of response as assessed by investigator and independent central review per RECIST v1.1; progression-free survival; and long-term requirements for cancer-related medical resources post ATL001 therapy."

Answered by AI
~0 spots leftby Mar 2025